A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
نویسندگان
چکیده
منابع مشابه
Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia.
mAb (eculizumab), investigators also used an ELISA that measured C5a/C5a(desArg). Regardless, we suspect that eculizumab blocks generation of C5a in sensitized red cell assays (ex vivo) but may not prevent enzymatic generation of C5a in vivo. Although C5 blockade has proven efficacious in a variety of clinical disorders, further research is warranted to assess the potential benefits or harms of...
متن کاملTumor Lysis Syndrome
Hospital Physician September 2008 25 T umor lysis syndrome (TLS) is a collection of metabolic abnormalities that occur as a result of the release of intracellular contents following lysis of malignant cells, typically after initiation of chemotherapy. The features of TLS include hyperphosphatemia, hyperuricemia, hypocalcemia, hyperkalemia, and acute kidney injury. These features are observed wh...
متن کاملSpontaneous Tumor Lysis Syndrome
Tumor lysis syndrome (TLS) is a known complication of malignancy and its treatment. The incidence varies on malignancy type, but is most common with hematologic neoplasms during cytotoxic treatment. Spontaneous TLS is thought to be rare. This case study is of a 62-year-old female admitted with multisystem organ failure, with subsequent diagnosis of aggressive B cell lymphoma. On admission, labo...
متن کاملThe tumor lysis syndrome.
From the Department of Oncology and International Outreach Program, St. Jude Children’s Research Hospital (S.C.H., C.-H.P.), and the Department of Pediatrics, University of Tennessee Health Sciences Center, College of Medicine (S.C.H., D.P.J., C.-H.P.) — both in Memphis. Address reprint requests to Dr. Howard at St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Barry-Longinotti Bld...
متن کاملOncologic Emergencies: Tumor Lysis Syndrome
The tumor lysis syndrome (TLS), characterized by hyperkalemia, hyperuricemia, hyperphosphatemia and secondary hypocalcemia, is a consequence of treatmentinduced or spontaneous tumor cell death. It usually occurs a few hours to a few days after commencing cytotoxic chemotherapy for tumors with a high percentage of proliferating and drug-sensitive cells. Cell death leads to the release of potassi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medeniyet Medical Journal
سال: 2021
ISSN: 2149-2042
DOI: 10.5222/mmj.2021.56424